Diabetes

Dasiglucagon (Zegalogue; Zealand Pharma) showed clear clinical benefit in median time to blood glucose recovery, according to 3 clinical trials.

Once-weekly semaglutide 2.4 mg resulted in sustained reductions in weight for those who are overweight or obese, the investigators reported.

Insulin resistance and type 2 diabetes were major contributors to premature coronary heart disease, according to the study results.

Pharmacists can help patients through education, therapy, and lifestyle modifications.

The latest Heart Disease and Stroke Statistical Update highlighted pandemic-related trends that may impact cardiovascular disease mortality for years.

A recent study examined patient characteristics and factors affecting COVID-19 mortality in individuals with diabetes.

A recent study examined how insulin levels and body mass index may have ties to mental health concerns.

Investigators compared outcomes among patients with COVID-19 and hypertension through modifying blood pressure medication use.

Over-the-counter product selection for patients with diabetes.

The agency granted priority review to dapagliflozin (Farxiga; AstraZeneca) for the treatment of new or worsening chronic kidney disease in adults with and without type 2 diabetes.

The Drug Topics® team rounded up some of our top-read articles from the last year.

A study to be presented at the annual meeting of the Radiological Society of North America reported that COVID-19 patients with diabetes and hypertension may have a higher risk for neurologic complications.

What pharmacists need to know about helping patients navigate changing landscape.

Researchers reported that patients who received finerenone had a lower risk of kidney failure or death from renal causes.

A subgroup analysis of the DAPA-CKD phase 3 trial reported on the continued benefit of dapagliflozin in patients with chronic kidney disease, regardless of underlying cause.

Patients now have a variety of options to help them lose weight, and pharmacists can offer a variety of specialized services to support their patients’ needs.

Investigators compared SGLT2 inhibitors with DPP-4 inhibitors to evaluate their effects on the risk of major heart problems.

Sun Pharmaceuticals issued a voluntary recall of 1 lot of its metformin hydrochloride for extended-release (ER) oral suspension (Riomet ER), 500 mg per 5 mL.

In a post-hoc analysis, researchers reported the effects of semaglutide on kidney function in patients with type 2 diabetes.

The study marks the first pharmacoepigenetic study in diabetes evaluating epigenetic factors as biomarkers to predict a drug’s effects on an individual.

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

The MiniMed 770G system (Medtronic) is approved for use by individuals aged 2 to 6 with type 1 diabetes.

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

The removal of the boxed warning from canagliflozin was based on the FDA’s review of new data from 3 clinical trials.